The estimated Net Worth of Benjamin Maynor is at least $119 Tysiąc dollars as of 27 May 2020. Benjamin Maynor owns over 4,754 units of Liquidia Corp stock worth over $119,110 and over the last 6 years he sold LQDA stock worth over $0. In addition, he makes $0 as Senior Vice President - Research & Development at Liquidia Corp.
Benjamin has made over 3 trades of the Liquidia Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 4,754 units of LQDA stock worth $12,788 on 27 May 2020.
The largest trade he's ever made was exercising 6,132 units of Liquidia Corp stock on 14 April 2020 worth over $11,344. On average, Benjamin trades about 2,615 units every 91 days since 2019. As of 27 May 2020 he still owns at least 11,735 units of Liquidia Corp stock.
You can see the complete history of Benjamin Maynor stock trades at the bottom of the page.
Dr. Benjamin Maynor Ph.D. serves as Senior Vice President - Research & Development of the Company. He joined us as a scientist in September 2005 and is a co-inventor of our PRINT technology. Dr. Maynor was seconded by us to Envisia Therapeutics Inc. from January 2013 to March 2015 where he served as Envisia's vice president, research. Dr. Maynor was also our Vice President, Research from January 2012 to January 2013, our Executive Director of Research from November 2011 to January 2012, our Director of Research from January 2010 to November 2011, our Principal Scientist from October 2009 to January 2010 and a Scientist of the Company from September 2005 to October 2009. Prior to joining us, Dr. Maynor was a postdoctoral associate at UNC from May 2004 to September 2005. He was also a scientist at Polestar Technologies, Inc. from September 1996 to June 1999. Dr. Maynor graduated from Harvard University with a Bachelor of Arts in Chemistry. He also holds a Doctor of Philosophy in Chemistry from Duke University. He is also a member of both the American Chemical Society and the American Association of Pharmaceutical Scientists. Dr. Maynor was honored with the Kathryn C. Hach Award for Entrepreneurial Success in 2014 by the American Chemical Society.
Benjamin Maynor is 45, he's been the Senior Vice President - Research & Development of Liquidia Corp since 2016. There are 18 older and 1 younger executives at Liquidia Corp. The oldest executive at Liquidia Corp is Ralph Snyderman, 80, who is the Independent Director.
Benjamin's mailing address filed with the SEC is 419 DAVIS DRIVE, SUITE 100, , MORRISVILLE, NC, 27560.
Over the last 6 years, insiders at Liquidia Corp have traded over $16,750,945 worth of Liquidia Corp stock and bought 12,456,625 units worth $100,694,400 . The most active insiders traders include Forest Baskett, Scott D Sandell oraz Peter J Barris. On average, Liquidia Corp executives and independent directors trade stock every 18 days with the average trade being worth of $1,467,274. The most recent stock trade was executed by Russell Schundler on 30 August 2024, trading 2,344 units of LQDA stock currently worth $23,792.
liquidia technologies is a biopharmaceutical company transforming the development of new therapies by precisely engineering drug particles. our proprietary print technology is a simple, elegant solution that solves common problems with drug delivery and efficacy. print technology is a scalable cgmp compliant process that creates particles and can apply to virtually any therapeutic area, molecule or route of administration. liquidia is bringing more efficient, controlled development capabilities to the industry while enhancing the safety and quality of products for patients. liquidia is advancing product candidates from its own pipeline. these initial product candidates, liq861 and liq865, apply the print technology to better drug delivery in inhaled and pain therapeutic areas, respectively. the print technology is also licensed with world-leading pharmaceutical companies that are developing future product candidates.
Liquidia Corp executives and other stock owners filed with the SEC include: